-
Mashup Score: 53
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51
Matthew Matasar, MD, is a medical oncologist specializing in lymphoma and is chief of the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. When I last was up for recertification for medical oncology, I realized with a sense of long-suppressed dread that I was going to fail. After all, I’m an academic oncologist who focuses on one thing and one thing only — lymphoma — and that’s not good when it comes to the boards. Hematologic malignancies make up a whopping
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 69th Translational Research Conference: Myelodysplastic Syndromes | ESH - European School of Haematology - 5 month(s) ago
Chairs : Pierre Fenaux, Katharina Götze, Mikkael Sekeres SAVE THE DATE! April 12-14, 2024 – Budapest, Hungary Chairs: Pierre Fenaux, Katharina G ö tze, Mikkael Sekeres REGISTRATION & ABSTRACT SUBMISSION ARE OPEN! ABOUT THE CONFERENCE: ESH 9 th TRANSLATIONAL RESEARCH CONFERENCE ON MYELODYSPLASTIC SYNDROMES proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international
Source: www.esh.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Health care workers facing violence in the ER need more than just safety — they need security.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Singulair, now a generic, is still used by millions of people in the United States even after thousands of patients and dozens of studies have described harm.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Singulair, now a generic, is still used by millions of people in the United States even after thousands of patients and dozens of studies have described harm.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Singulair, now a generic, is still used by millions of people in the United States even after thousands of patients and dozens of studies have described harm.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Opinion | Our Semicolons, Ourselves - 5 month(s) ago
A.I. or no A.I., it pays to write — and to write well.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Mikkael Sekeres on Therapies for Hematologic Cancers - The ASCO Post - 5 month(s) ago
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425). William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
Love this @ASHClinicalNews editorial joining the chorus to blast the absurdity of ABIM's MOC, "a recertification system woefully misaligned with its avowed purpose: to ensure that practicing physicians possess clinical competence |To Kill a MOC(kingbird) https://t.co/yUxi6fBXUC